Mirum
OrganizationHeard in 2 episodes across 2 shows since Oct 2026
Mirum Pharmaceuticals is a biopharmaceutical company developing and commercializing treatments for rare liver diseases.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 1 |
| Nov 2026 | 1 |
Email alert
Email me when Mirum comes up on a podcast
One email a week at most, with the new episodes that mention Mirum. Free, no account needed, unsubscribe in one click.
What experts have said about Mirum
5 statements · 5 positive
Mirum is expected to generate over $700 million in marketed-franchise sales this year.
“The company is going to sell about 700 plus million dollars of sales this year in their marketed franchise.”
Open the episode · The Quality Growth Playbook for Biotech | David FerreiroListen at 10:12
Mirum's PSC opportunity could address 20,000 patients starting next year.
“this could be a 20,000 patient market opportunity that could start for them next year”
Open the episode · The Quality Growth Playbook for Biotech | David FerreiroListen at 11:44
Mirum acquired an FOP opportunity worth $200 million for under $100 million including milestones.
“$200 million opportunity that they basically paid something less than $100 million after you tie in all the milestones.”
Open the episode · The Quality Growth Playbook for Biotech | David FerreiroListen at 12:35
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
2 episodes featuring Mirum, newest first
